OphthaliX Signs Definitive Agreement to Acquire Improved Vision Systems Ltd.
December 15, 2014
Second Part of the Glaucoma Phase II study has been Approved in a European Country
September 6, 2014
OphthaliX Provides an Update on its Clinical Developments and Strategic Plans
December 31, 2013
OphthaliX to Conduct a Retrospective Analysis of the Phase III Dry Eye Syndrome Study Data Based on the A3 Adenosine Receptor Biomarker
December 30, 2013
OphthaliX Announces Top-Line Results of Phase III Study with CF101 for Dry Eye Syndrome
November 5, 2013
U.S. Patent and Trademark Office Grants a Patent for the Reduction of Intraocular Pressure
October 2, 2013
OphthaliX to Present at the Ophthalmology Futures European Forum
September 3, 2013
European Patent Office Grants a Patent for the Treatment of Sjogren`s Syndrome
July 17, 2013
OphthaliX to Initiate a Phase II study of CF101 for the Treatment of Uveitis
July 2, 2013
OphthaliX Appoints Dr. Michael Belkin to its Board of Directors
May 12, 2013
Third Party Presented New Data at the ARVO 2013 Annual Meeting in Seattle, WA, Validating the use of A3 Adenosine Receptor Agonists for Lowering Intra Ocular Pressure and for the Treatment of Glaucoma
March 17, 2013
OphthaliX Inc. Announces the Completion of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study
December 13, 2012
Dr. Gil Ben-Menachem appointed Chief Executive Officer of OphthaliX Inc
April 9, 2012
OphthaliX Successfully Completed Preclinical Studies Showing the Efficacy of CF101 for the Treatment of Anterior Uveitis
February 22, 2012
OphthaliX announces issuance of Chinese Patent for the treatment of Dry Eye Disorders
February 6, 2012
OphthaliX announces the appointment of Prof. Roger Kornberg as a Director.
January 31, 2012
Denali Concrete Management Inc. Announces its Effective Name Change to OphthaliX Inc. On February 1, 2012, OphthaliX`s Trading Symbol Will Change from DCMG to OPLI.
December 21, 2011
Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study.
November 22, 2011
Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share.